U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C19H18N4O2.C6H8O7
Molecular Weight 526.4953
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of AZD-1080 CITRATE

SMILES

OC(=O)CC(O)(CC(O)=O)C(O)=O.OC1=C(C2=C(N1)C=CC(=C2)C#N)C3=CC=C(CN4CCOCC4)C=N3

InChI

InChIKey=QIXMKFAORYGAFN-UHFFFAOYSA-N
InChI=1S/C19H18N4O2.C6H8O7/c20-10-13-1-3-16-15(9-13)18(19(24)22-16)17-4-2-14(11-21-17)12-23-5-7-25-8-6-23;7-3(8)1-6(13,5(11)12)2-4(9)10/h1-4,9,11,22,24H,5-8,12H2;13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)

HIDE SMILES / InChI
Molecular Formula C6H8O7
Molecular Weight 192.1235
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula C19H18N4O2
Molecular Weight 334.3718
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

AZ-1080 (AZD-1080) is an inhibitor of GSK-beta which was developed by AstraZeneca and initially tested in patients with Alzheimer’s disease (phase I). The drug was discontinued for the aforementioned condition, but now it is being investigated as a potential therapy for ovarina cancer and emdometrial carcinoma (basic research).

CNS Activity

Originator

Approval Year

Unknown
149124
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8504
 31.0 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Phase I
438
Unknown

Approved Use

Unknown
Primary
Basic research
Unknown

Approved Use

Unknown
Primary
Basic research
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
86 nM
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/23410232
15 mg 1 times / day steady-state, oral
dose: 15 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
AZD-1080 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
20 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/23410232
15 mg 1 times / day steady-state, oral
dose: 15 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
AZD-1080 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
15 mg 1 times / day steady-state, oral
Studied dose
Dose: 15 mg, 1 times / day
Route: oral
Route: steady-state
Dose: 15 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/23410232
healthy, ADULT
Health Status: healthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/23410232
Sources:
https://pubmed.ncbi.nlm.nih.gov/23410232
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
inhibitor
2252
inhibitor
2438
inhibitor
2507

OverviewOther

Other InhibitorOther SubstrateOther Inducer
P-gp
1741
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
P-gp
1932
 inconclusive [IC50 29.0929 uM]
CYP2C9
2497
 yes [IC50 16.933 uM]
CYP3A4
2633
 yes [IC50 6.0081 uM]
CYP2D6
2546
 yes [IC50 6.7412 uM]
Sourcing

Sourcing

Vendor/AggregatorIDURL
1PlusChem LLC
1P003EV6
https://www.1pchem.com/search?query=1P003EV6
AChemBlock
M15675
http://www.achemblock.com/catalogsearch/result/?q=M15675
AK Scientific
X6996
https://aksci.com/item_detail.php?cat=X6996
Ambeed
A166126
http://www.ambeed.com/search/Search.html?keyword=A166126
Angene
AGN-PC-0SZJUP
http://www.angenechemical.com/productshow/AGN-PC-0SZJUP.html
AOBIOUS INC
AOB87345
http://aobious.com/aobious/search?search_query=AOB87345
AstaTech
F17385
http://astatechinc.com/CPSResult.php?CRNO=F17385
Axon MedChem
2171
https://www.axonmedchem.com/product/2171
BLD Pharm
BD328422
http://www.bldpharm.com/search/Search.html?keyword=BD328422
Cayman Chemical
16676
http://www.caymanchem.com/app/template/Product.vm/catalog/16676
ChemShuttle
110107
https://www.chemshuttle.com/catalogsearch/result/?q=110107
Combi-Blocks
QW-5453
http://www.combi-blocks.com/cgi-bin/find.cgi?QW-5453
eMolecules
48544545
https://orderbb.emolecules.com/search/#?query=48544545
eNovation Chemicals
D372289
https://www.enovationchem.com/Products.asp?SEARCHTEXT=D372289&searchbtn.x=0&searchbtn.y=0
Excenen
EX-A230
http://www.excenen.com/searchresultlist.php?id=EX-A230
KeyOrganics
AS-55896
http://www.keyorganicsinc.com/bionet/catalogsearch/result?q=AS-55896
Lab Network
LN01274605
https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN01274605
Matrix Scientific
146803
http://www.matrixscientific.com/146803.html
MedChem Express
HY-13862
https://www.medchemexpress.com/search.html?q=HY-13862&ft=&fa=&fp=
MolPort
MolPort-028-754-155
https://www.molport.com/shop/molecule-link/MolPort-028-754-155
MuseChem
I004307
https://www.musechem.com/product/I004307.html
Ryan Scientific
101-94140
https://ryansci.com/products?q=101-94140&list_q=&search_type=exact
Selleck Chemicals
S7145
http://www.selleckchem.com/search.html?searchDTO.searchParam=S7145
ShangHai Biochempartner
BCP000938
http://www.biochempartner.com/search_BCP000938
ShangHai Biochempartner
BCP07919
http://www.biochempartner.com/search_BCP07919
Toronto Research Chemicals
A808085
https://www.trc-canada.com/product-detail/?CatNum=A808085
PubMed

PubMed

TitleDatePubMed
The role of glycogen synthase kinase-3β (GSK-3β) in endometrial carcinoma: A carcinogenesis, progression, prognosis, and target therapy marker.
2016-05-10
Role of glycogen synthase kinase-3β inhibitor AZD1080 in ovarian cancer.
2016
Differential effects of glycogen synthase kinase 3 (GSK3) inhibition by lithium or selective inhibitors in the central nervous system.
2013-10
AZD1080, a novel GSK3 inhibitor, rescues synaptic plasticity deficits in rodent brain and exhibits peripheral target engagement in humans.
2013-05
Patents

Patents

WO2003082853 A1
2

Sample Use Guides

In Vivo Use Guide
Middle-aged subjects (45–64 years) receive 15 mg AZ-1080 once daily for 14 days.
Route of Administration: Oral
In Vitro Use Guide
3T3 fibroblasts stably expressing human tau protein were treated with 1 uM of AZ-1080. Dose-dependent inhibition of tau phosphorylation was observed for AZ-1080 with IC50 value of 324 nM.
Substance Class Chemical
Created
by admin
on Wed Apr 02 19:34:31 GMT 2025
Edited
by admin
on Wed Apr 02 19:34:31 GMT 2025
Record UNII
Y2785L6ZLV
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
AZD1080 CITRATE
Preferred Name English
AZD-1080 CITRATE
Code English
2-Hydroxy-3-[5-[(morpholin-4-yl)methyl]pyridin-2-yl]-1H-indole-5-carbonitrile citrate
Systematic Name English
1H-Indole-5-carbonitrile, 2-hydroxy-3-[5-(4-morpholinylmethyl)-2-pyridinyl]-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1)
Common Name English
Code System Code Type Description
FDA UNII
Y2785L6ZLV
Created by admin on Wed Apr 02 19:34:31 GMT 2025 , Edited by admin on Wed Apr 02 19:34:31 GMT 2025
PRIMARY
PUBCHEM
135802773
Created by admin on Wed Apr 02 19:34:31 GMT 2025 , Edited by admin on Wed Apr 02 19:34:31 GMT 2025
PRIMARY
CAS
945633-71-6
Created by admin on Wed Apr 02 19:34:31 GMT 2025 , Edited by admin on Wed Apr 02 19:34:31 GMT 2025
PRIMARY
Related Record Type Details
Structure of AZD-1080
PARENT -> SALT/SOLVATE
Related Record Type Details
Structure of AZD-1080
ACTIVE MOIETY
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966